Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Take Regeneron Pharmaceuticals(NASDAQ ... And with Morgan Stanley's prediction that the global weight-loss drug market could swell from last year's $15 billion to a peak of $150 billion by 2035, there ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Note that some links may require registration or subscription. Justin Timberlake said he has been diagnosed with Lyme disease ...

Detailed price information for Lexaria Bioscience Corp WT (LEXXW-Q) from The Globe and Mail including charting and trades.

The S&P 500 Index ($SPX) (SPY) today is down -1.70%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -1.48%, and the ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...